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Bisplatinum complexes are a promising new class of structurally unique 
dimeric antitumor agents [11 exhibiting novel DNA binding properties I2]. In 
the interest of elucidating key structure-activity relationships (SAR), and thus 
identifying optimally active complexes, substituted bisptatinum complexes of 
the generic structure (Figure) were synthesized and evaluated in sensitive and 
platinum(Pt)-resistant cell li~es in vigr¢'; (L1210, P388) a~xt. i, ~, vivo (i. 12105: 
X2(A)PtNH2-L-NH2Pt(A)X 2 ! 
In 1, L represents a straight-chain or functionalized hydrocarlxm moiety 
(linker group) having a linker length (n) of 4 to 6 atoms; X (or X 2) represents 
chloride or malonate leaving groups, and A is either NH 3 or EtNH 2. In 
principle, varying L allows one to modify the physical and structural 
properties of 1, as relates to enhanced specificity and affinity of DNA binding 
as well as to optimal aqueous solubility. Nine categones of complexes can be 
identified based on the organic nature of the linker group. CompIexes were 




1 + 4AgNO 3 
~. {2K[PtAIa]} H2N-L-NH2 1 )X = I) ( I )  
Na(tt)C1 
,.- 1 ( x  = H 2 0 )  ~ i (X = e l )  ( 2a )  
1 + 2 Ag2C3H204 (s) I (X 2 = malonate) ( 2 b )  
Antitumor testing and SAR data indicate that (1) significant activity was 
observed in vivo in L1210 leukemia, Colon 26 carcinoma, and to a lesser 
extent, in AH 125 non-small cell lung carcinoma; (2) activity is curative for 
the parent system (L=--(CH2)5-, X=Ct) and the analog, L:: -(CH2)6--, X2= 
malonate; (3) monoalkylsubstitution (n = 5,6) and monosubstitutior~ in the 
3-position (n= 5) appear to be optimal. More specifically, the potency of the 
3-hydroxy analog is approximately t0x higher than thin of the complex 
[Pt(DACH)C12]; and (4) monoalkyl substitution leads to comparable potency 
but higher resistance factors relative to the parent svstem, o 
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